Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

No phase data

Trial Status

Other2

Role Distribution

Principal Investigator2
PI Rate100%

Activity Timeline

Clinical Trials (2)

NCT03795779Early Phase 1Unknown
CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies
Acute Myeloid LeukemiaChronic Myeloid LeukemiaHematologic Malignancy+2 more
PrincipalinvestigatorStart date: 2018-03-01
NCT04156243Early Phase 1Unknown
CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies
B Cell LeukemiaB Cell Lymphoma
PrincipalinvestigatorStart date: 2018-02-01

Research Network

Collaboration Network

3 collaborators·2 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Hongyu Zhang, MD, PhD

Peking University Shenzhen Hospital

Very Similar
5 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcuteLeukemia, B-CellLymphoma, B-Cell+4 more

Worked with same sponsors:

Chengdu Military General HospitaliCAR Bio Therapeutics Ltd.+3 more
Collaborated on 2 trials
Similarity Score78%

Yifan Zhai, MD, PhD

Ascentage Pharma Group Inc.

Related
14 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcuteLymphoma, B-CellLeukemia, Myelogenous, Chronic, BCR-ABL Positive+2 more
Similarity Score21%

Qifa Liu

Nanfang Hospital, Southern Medical University

Related
33 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcuteMyelodysplastic SyndromesHematologic Neoplasms+1 more

Worked with same sponsors:

Peking University Shenzhen Hospital
Similarity Score17%

Mary Horowitz, MD

Center for International Blood and Marrow Transplant Research

Related
24 trials

Shared therapeutic areas:

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, AcuteLymphoma, B-Cell+1 more
Similarity Score17%

Richard W Childs, M.D.

National Heart, Lung, and Blood Institute (NHLBI)

Related
15 trials

Shared therapeutic areas:

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, AcuteHematologic Neoplasms+1 more
Similarity Score17%

Arnon Nagler, MD

Chaim Sheba Medical Center

Related
12 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcuteLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMyelodysplastic Syndromes+1 more
Similarity Score17%

Yves Beguin, MD, PhD

CHU-ULg

Related
7 trials

Shared therapeutic areas:

Hematologic NeoplasmsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, Acute+1 more
Similarity Score17%

Beata Holkova, MD

Massey Cancer Center

Related
3 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcuteLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMyelodysplastic Syndromes
Similarity Score13%

Areej El-Jawahri, MD

Massachusetts General Hospital

Related
21 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcuteHematologic NeoplasmsMyelodysplastic Syndromes
Similarity Score13%

Jorge Cortes, MD

M.D. Anderson Cancer Center

Related
24 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcuteLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMyelodysplastic Syndromes
Similarity Score13%

Publications (0)

No publications found for this investigator.

Clinical Trials (2)

Showing 2 of 2 trials

NCT03795779Early Phase 1PrincipalInvestigator

CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Acute Myeloid LeukemiaChronic Myeloid LeukemiaHematologic Malignancy+2 more
Unknown
NCT04156243Early Phase 1PrincipalInvestigator

CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies

B Cell LeukemiaB Cell Lymphoma
Unknown

All 2 trials loaded